Literature DB >> 14645403

David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies.

Brian J Druker1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14645403     DOI： 10.1200/JCO.2003.10.589

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

1.  Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.

Authors:  Brian J Park; Zakary L Whichard; Seth J Corey
Journal:  Cancer Lett       Date:  2012-02-02       Impact factor: 8.679

Review 2.  Immunotherapy meets targeted therapy: will this team end the war against cancer?

Authors:  Daniela Morales-Espinosa; Silvia García-Román; Cristina Teixidó; Niki Karachaliou; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2015-12

3.  Can the chemotherapeutic agents perform anticancer activity through miRNA expression regulation? Proposing a new hypothesis [corrected].

Authors:  Chiranjib Chakraborty; C George Priya Doss; Renu Sarin; Minna J Hsu; Govindasamy Agoramoorthy
Journal:  Protoplasma       Date:  2015-02-20       Impact factor: 3.356

4.  The Arf/p53 protein module, which induces apoptosis, down-regulates histone H2AX to allow normal cells to survive in the presence of anti-cancer drugs.

Authors:  Yuko Atsumi; Aki Inase; Tomoyuki Osawa; Eiji Sugihara; Ryo Sakasai; Hiroaki Fujimori; Hirobumi Teraoka; Hideyuki Saya; Masamoto Kanno; Fumio Tashiro; Hitoshi Nakagama; Mitsuko Masutani; Ken-ichi Yoshioka
Journal:  J Biol Chem       Date:  2013-03-27       Impact factor: 5.157

Review 5.  Combining immunotherapy and targeted therapies in cancer treatment.

Authors:  Matthew Vanneman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

6.  Computational methods and opportunities for phosphorylation network medicine.

Authors:  Yian Ann Chen; Steven A Eschrich
Journal:  Transl Cancer Res       Date:  2014-06-01       Impact factor: 1.241

Review 7.  Proteomic contributions to personalized cancer care.

Authors:  John M Koomen; Eric B Haura; Gerold Bepler; Rebecca Sutphen; Elizabeth R Remily-Wood; Kaaron Benson; Mohamad Hussein; Lori A Hazlehurst; Timothy J Yeatman; Lynne T Hildreth; Thomas A Sellers; Paul B Jacobsen; David A Fenstermacher; William S Dalton
Journal:  Mol Cell Proteomics       Date:  2008-07-29       Impact factor: 5.911

Review 8.  It's about time: lessons for solid tumors from chronic myelogenous leukemia therapy.

Authors:  Jason R Westin; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2012-11-30       Impact factor: 6.261

9.  Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis.

Authors:  Frank Kuhnert; Betty Y Y Tam; Barbara Sennino; John T Gray; Jenny Yuan; Angeline Jocson; Nihar R Nayak; Richard C Mulligan; Donald M McDonald; Calvin J Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-16       Impact factor: 11.205

10.  Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms.

Authors:  Masahisa Jinushi; Marimo Sato; Akira Kanamoto; Akihiko Itoh; Shigenori Nagai; Shigeo Koyasu; Glenn Dranoff; Hideaki Tahara
Journal:  J Exp Med       Date:  2009-05-11       Impact factor: 14.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.